The Latest Breaking News from AstraZeneca

London and Washington have found a compromise that would avoid US tariffs on British medicines — but only after the UK agreed to pay more for cutting-edge drugs.

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Shareholder-backed plans to upgrade US listing have exposed multiple flaws in tax that should be abolished or at least cut

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

On the FTSE 100, gold miners Fresnillo and Endeavour Mining leapt 9.1% and 11% respectively.

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

The president's road to settling on a plan to lower prescription drug costs was rocky.

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.